---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016388"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T05:27:33.812867+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics Q1 net loss $4.4M, cash $46.8M; OpRegen phase 2a enrolling

## Summary
- Revenue $2.4M, down 54% YoY from $5.2M due to lower Roche collaboration revenue.
- Net loss improved to $4.4M ($0.03/share) from $7.1M ($0.04/share) in Q1 2022.
- Cash equivalents and marketable securities $46.8M; expected to fund operations into Q3 2024.
- OpRegen Phase 2a for GA secondary to AMD continues enrolling; new sites expected in 2023.
- OPC1 granted US patent expiring no earlier than 2040; Type B meeting with FDA planned.

## SEC filing metadata
- accession: 0001493152-23-016388
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315223016388/0001493152-23-016388-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315223016388/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016388
- JSON: https://secwatch.observer/filing/0001493152-23-016388.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016388.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.